Indivior PLC $INDV Stock Acquired by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC increased its stake in shares of Indivior PLC (NASDAQ:INDV) by 831.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,642 shares of the company’s stock after purchasing an additional 18,427 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Indivior were worth $740,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Assenagon Asset Management S.A. lifted its holdings in Indivior by 129.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,540,344 shares of the company’s stock worth $126,921,000 after buying an additional 1,999,416 shares in the last quarter. Avior Wealth Management LLC bought a new position in Indivior in the 3rd quarter valued at $272,000. Farther Finance Advisors LLC boosted its position in Indivior by 716.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 3,624 shares of the company’s stock valued at $130,000 after buying an additional 3,180 shares during the last quarter. Artemis Investment Management LLP boosted its position in Indivior by 214.8% in the 3rd quarter. Artemis Investment Management LLP now owns 48,231 shares of the company’s stock valued at $1,729,000 after buying an additional 32,912 shares during the last quarter. Finally, Two Seas Capital LP increased its stake in shares of Indivior by 5.5% in the 3rd quarter. Two Seas Capital LP now owns 3,671,072 shares of the company’s stock valued at $131,608,000 after buying an additional 191,579 shares during the period. Institutional investors and hedge funds own 60.33% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on INDV shares. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 2nd. Craig Hallum reaffirmed a “buy” rating and set a $53.00 price target on shares of Indivior in a research note on Tuesday, August 4th. Weiss Ratings cut Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, September 24th. Finally, Barclays decreased their price target on Indivior from $46.00 to $43.00 and set an “overweight” rating on the stock in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Indivior presently has a consensus rating of “Buy” and an average price target of $45.17.

Insider Transactions at Indivior

In other Indivior news, CAO Woodrow D. Anderson bought 1,500 shares of the stock in a transaction on Thursday, August 27th. The stock was purchased at an average price of $35.69 per share, with a total value of $53,535.00. Following the acquisition, the chief accounting officer owned 27,638 shares of the company’s stock, valued at approximately $986,400.22. The trade was a 5.74% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.74% of the company’s stock.

Indivior Stock Up 0.5%

Shares of NASDAQ INDV opened at $34.72 on Wednesday. Indivior PLC has a 1 year low of $24.28 and a 1 year high of $42.81. The firm’s 50-day moving average is $35.41 and its 200-day moving average is $35.62.

Indivior (NASDAQ:INDV) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $5.75 EPS for the quarter. The business had revenue of $343.00 million for the quarter. As a group, analysts predict that Indivior PLC will post 3.66 earnings per share for the current fiscal year.

Indivior Dividend Announcement

The firm also recently disclosed a special dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 30th will be paid a $8.13 dividend.

Indivior Profile

Indivior PLC (NASDAQ:INDV) is a global pharmaceutical company focused on developing and commercializing medicines for substance use disorders and serious mental health conditions. Its portfolio is centered on treatments for opioid use disorder, opioid overdose, and related medical needs.

The company’s principal products include Sublocade, an extended-release buprenorphine injection for opioid use disorder; Suboxone, a buprenorphine and naloxone treatment available in film and other formulations; and Opvee, a nalmefene nasal spray intended for the emergency treatment of known or suspected opioid overdose.